Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Study on acute coronary syndromes shows new anti-thrombotic therapy effective, safer for patients

06.09.2005


A Canadian-led study involving researchers from 41 countries has demonstrated in a study of acute coronary syndromes (ACS) that a new anti-thrombotic therapy is safer and as effective as the traditional therapy used in preventing heart attacks, death and ischemia in people with serious heart conditions.



The OASIS-5/MICHELANGELO study, presented today at the European Society of Cardiology meeting in Stockholm, Sweden, showed that fondaparinux, a new anti-thrombotic therapy, was as effective as enoxaparin in preventing heart attacks, death and ischemia (reduction in blood supply to the tissues) at nine days after an event but demonstrated a dramatic reduction in major bleeding. The study indicated patients had a lower mortality rate at the one-month mark after an acute coronary event. This finding remained consistent throughout the following six months of follow-up.

These favourable effects resulted in a clear net benefit in favour of fondaparinux throughout the study, said Dr. Salim Yusuf, principal investigator and chair of the international study.


"The study findings demonstrate that fondaparinux is likely the anti-thrombotic drug of choice in patients with acute coronary syndromes who are already receiving aspirin and clopidogrel," said Dr. Yusuf, professor of medicine in the Michael G. DeGroote School of Medicine at McMaster University and director of the Population Health Research Institute, McMaster University and Hamilton Health Sciences in Hamilton, Ontario, Canada. "This is the first study in ACS patients that demonstrates that effective prevention of thrombotic events can be combined with a safer drug profile."

The OASIS-5/MICHELANGELO study was a multi-centre, randomized, double-blind, placebo-controlled trial involving more than 20,000 patients and was conducted at 576 sites in 41 countries. The primary objective was to evaluate the efficacy and safety of fondaparinux, a synthetic drug that acts specifically during the earlier part of the clotting cascade, with enoxaparin, a low molecular weight heparin that is commonly used as an anti-thrombotic therapy.

Previous studies have indicated that patients who experience a major bleed in acute coronary syndromes exhibit a much higher risk of death during the immediate weeks following the event. Anti-thrombotic therapies used in the last two decades have substantially decreased the risk of a heart attack but have also been associated with a significant increase in bleeding risks. Therefore, therapies that maintain the benefits of currently available anti-thrombotic therapies, but have less bleeding, are of great clinical importance, Dr. Yusuf said.

Dr. Shamir R. Mehta, project director of the international study, associate professor of medicine in the Michael G. DeGroote School of Medicine at McMaster University and an interventional cardiologist at Hamilton Health Sciences, remarked: "The fact that the benefits and safety of fondaparinux are observed on top of other effective treatments, such as aspirin, clopidogrel, GP IIb/IIIa inhibitors and revascularization procedures, emphasizes its value in a broad spectrum of patients with acute coronary syndromes."

Dr. Mehta added: "One of the most important findings of the trial was that fondaparinux was associated with a lower overall mortality at six months compared with enoxaparin. This is good news for patients in that doctors now have a therapy that will not only saves lives but is also substantially safer than current treatments."

Professor Keith Fox, professor of cardiology at the University of Edinburgh and co-chair of the study’s operation committee, added: "This study demonstrates that improving the safety of therapy leads to enhanced long-term survival for patients."

Dr. Yusuf noted that previous studies showed that fondaparinux was superior in preventing deep venous thrombosis when compared to enoxaparin. "The current findings extend the beneficial results from the venous side to high-risk individuals with atherothrombosis," he added.

The OASIS-5/MICHELANGELO study was supported by grants from Sanofi-Synthelabo, Organon, and Glaxo-Smith Kline. The OASIS network is led by researchers in the Population Health Research Institute, McMaster University and Hamilton Health Sciences and is an international collaboration of investigators who have completed some of the largest and most influential trials in heart disease that have contributed to enhanced patient care worldwide.

The Canadian Cardiovascular Collaboration Office is located at the Population Health Research Institute, McMaster University and Hamilton Health Sciences and is one of Canada’s leading research institutions. The experts at this institution are recognized internationally for their leading edge research, innovation, and excellence in cardiovascular sciences and thrombosis.

Gina Dellios | EurekAlert!
Further information:
http://www.escardio.org

More articles from Studies and Analyses:

nachricht WAKE-UP provides new treatment option for stroke patients | International study led by UKE
17.05.2018 | Universitätsklinikum Hamburg-Eppendorf

nachricht First form of therapy for childhood dementia CLN2 developed
25.04.2018 | Universitätsklinikum Hamburg-Eppendorf

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Molecular switch will facilitate the development of pioneering electro-optical devices

A research team led by physicists at the Technical University of Munich (TUM) has developed molecular nanoswitches that can be toggled between two structurally different states using an applied voltage. They can serve as the basis for a pioneering class of devices that could replace silicon-based components with organic molecules.

The development of new electronic technologies drives the incessant reduction of functional component sizes. In the context of an international collaborative...

Im Focus: LZH showcases laser material processing of tomorrow at the LASYS 2018

At the LASYS 2018, from June 5th to 7th, the Laser Zentrum Hannover e.V. (LZH) will be showcasing processes for the laser material processing of tomorrow in hall 4 at stand 4E75. With blown bomb shells the LZH will present first results of a research project on civil security.

At this year's LASYS, the LZH will exhibit light-based processes such as cutting, welding, ablation and structuring as well as additive manufacturing for...

Im Focus: Self-illuminating pixels for a new display generation

There are videos on the internet that can make one marvel at technology. For example, a smartphone is casually bent around the arm or a thin-film display is rolled in all directions and with almost every diameter. From the user's point of view, this looks fantastic. From a professional point of view, however, the question arises: Is that already possible?

At Display Week 2018, scientists from the Fraunhofer Institute for Applied Polymer Research IAP will be demonstrating today’s technological possibilities and...

Im Focus: Explanation for puzzling quantum oscillations has been found

So-called quantum many-body scars allow quantum systems to stay out of equilibrium much longer, explaining experiment | Study published in Nature Physics

Recently, researchers from Harvard and MIT succeeded in trapping a record 53 atoms and individually controlling their quantum state, realizing what is called a...

Im Focus: Dozens of binaries from Milky Way's globular clusters could be detectable by LISA

Next-generation gravitational wave detector in space will complement LIGO on Earth

The historic first detection of gravitational waves from colliding black holes far outside our galaxy opened a new window to understanding the universe. A...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Save the date: Forum European Neuroscience – 07-11 July 2018 in Berlin, Germany

02.05.2018 | Event News

Invitation to the upcoming "Current Topics in Bioinformatics: Big Data in Genomics and Medicine"

13.04.2018 | Event News

Unique scope of UV LED technologies and applications presented in Berlin: ICULTA-2018

12.04.2018 | Event News

 
Latest News

If solubilty is the problem - Mechanochemistry is the solution

25.05.2018 | Life Sciences

Investigating cell membranes: researchers develop a substance mimicking a vital membrane component

25.05.2018 | Interdisciplinary Research

When corals eat plastics

24.05.2018 | Ecology, The Environment and Conservation

VideoLinks
Science & Research
Overview of more VideoLinks >>>